Ultime notizie per Concentrix (NASDAQ:CNXC) Azioni

Concentrix

CNX Coal Resources

Concentrix Corp is a technology-enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five primary industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Canada, Germany, Great Britain and others.

Concentrix Corp

The most oversold stocks in the industrials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Rentokil Initial plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTO#NYSE">RTO</a>)</h3>
<ul>
<li>On Sept. 11, Rentokil Initial revised the guidance for the second half of FY24. The company projects organic revenue growth for North America operations to be about 1% in the second half of 2024, with operating profit anticipated to be impacted by higher sales, service, and other costs. The company's stock fell around 25% over the past month and has a <a href="https://www.benzinga.com/quote/RTO">52-week low of $23.39</a>.</li>
<li>RSI Value: 29.83</li>
<li>RTO Price Action: Shares of Rentokil Initial fell 0.6% to close at $23.55 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100924&amp;t=be2bearmibe3na1">latest RTO news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09063801/image-56.png" alt="" class="wp-image-587289" style="width:726px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09063801/image-56.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09063801/image-56-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09063801/image-56-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Blue Bird Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On Oct. 3, Roth MKM analyst Craig Irwin downgraded Blue Bird from Buy to Neutral and maintained the price target of $48. The company's stock fell around 10% over the past five days. It <a href="https://www.benzinga.com/quote/BLBD">has a 52-week low</a> of $17.60.</li>
<li>RSI Value: 27.62</li>
<li>BLBD Price Action: Shares of Blue Bird fell 1.8% to close at $41.28 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100924&amp;t=be2bearmibe3na1">trend in BLBD stock</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100924&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/8d1535b6-9ac9-4100-90d5-ea90400c8d40" alt="" style="width:688px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Concentrix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>)</h3>
<ul>
<li>On Oct. 3, Baird analyst David Koning initiated coverage on Concentrix with an Outperform rating and announced a price target of $70. The company's shares fell around 32% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/CNXC">low of $48.71</a>.</li>
<li>RSI Value: 17.33</li>
<li>CNXC Price Action: Shares of Concentrix fell 5.6% to close at $48.74 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100924&amp;t=be2bearmibe3na1">breakout in CNXC shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent100924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="892" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09063944/image-58.png" alt="" class="wp-image-587298" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09063944/image-58.png 892w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09063944/image-58-300x285.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09063944/image-58-768x729.png 768w" sizes="(max-width: 892px) 100vw, 892px" /></a></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41238686/jim-cramer-ast-spacemobile-is-just-too-hot-recommends-buying-this-tech-stock">Jim Cramer: AST SpaceMobile Is &#8216;Just Too Hot,&#8217; Recommends Buying This Tech Stock</a></li>
</ul>

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

BLBD

CNXC

Top 3 Industrials Stocks Which Could Blast Off This Quarter

Baird analyst David Koning initiates coverage on Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Outperform rating and announces Price Target of $70.

Price Target

Initiation

Analyst Ratings

Baird Initiates Coverage On Concentrix with Outperform Rating, Announces Price Target of $70

U.S. stocks traded higher toward the end of trading, with the Dow Jones index rising more than 250 points on Thursday.
The Dow traded up 0.63% to 42,177.28 while the NASDAQ rose 0.54% to 18,179.88. The S&amp;P 500 also rose, gaining, 0.36% to 5,743.03.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41045161/how-to-earn-500-a-month-from-costco-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Costco Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Materials shares jumped by 1.9% on Thursday.
In trading on Thursday, energy shares fell by 2%.
Top Headline
Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) reported better-than-expected earnings for its fourth quarter.
The company posted quarterly sales of $16.41 billion compared with the analyst consensus estimate of $16.39 billion, up 3% Y/Y in U.S. dollars and 5% in local currency. The adjusted EPS of $2.79 topped the analyst consensus estimate of $2.77.
Accenture declared a quarterly cash dividend of $1.48 per share, implying a growth of 15%. The board approved $4.0 billion in additional share repurchase authority, bringing Accenture's total outstanding authority to approximately $6.7 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares shot up 43% to $3.31 after the company announced a partnership with Beckman Coulter Life Sciences to revolutionize DNA and mRNA synthesis.</li>
<li>Shares of Pasithea Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) got a boost, surging 62% to $6.24 after the company announced safety, tolerability, pharmacokinetic and preliminary efficacy data from the first 2 cohorts of patients in its Phase 1 clinical trial of PAS-004.</li>
<li>Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) shares were also up, gaining 11% to $125.56 after the company reported better-than-expected fourth-quarter financial results and approved a $1 billion share buyback.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) shares dropped 16% to $53.29 following mixed third-quarter financial results.</li>
<li>Shares of Ryde Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NYSE">RYDE</a>) were down 32% to $0.7792 after the company announced a $4.5 million public offering at $0.85 per unit.</li>
<li>MDxHealth SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) was down, falling 21% to $2.00 after the company announced the pricing of a $40 million offering of 20 million shares at $2.00 per share</li>
</ul>
Commodities In commodity news, oil traded down 2.5% to $67.95 while gold traded up 0.2% at $2,690.70.
Silver traded up 0.9% to $32.315 on Thursday, while copper rose 3.1% to $4.6290.
Euro zone
European shares closed higher today. The eurozone's STOXX 600 gained 1.25%, Germany's DAX climbed 1.69% and France's CAC 40 jumped 2.33%. Spain's IBEX 35 Index rose 1.36%, while London's FTSE 100 rose 0.20%.
Bank lending to households in the Eurozone increased by 0.6% year-over-year to €6.891 trillion in August compared to a 0.5% rise in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -21.2 heading into October versus a revised reading of -21.9 in the prior period.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 jumping 2.79%, Hong Kong's Hang Seng Index jumping 4.16%, China's Shanghai Composite Index gaining 3.61% and India's BSE Sensex gaining 0.78%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month.
Economics
<ul>
<li>U.S. core PCE prices increased by 2.8% from the prior quarter during the second quarter compared to a 3.7% gain in the previous period.</li>
<li>U.S. durable goods orders came in mostly unchanged from the previous month in August versus the revised 9.8% jump in the earlier period.</li>
<li>U.S. initial jobless claims fell by 4,000 from the prior week to 218,000 during the period ending September 21, compared to estimates of 225,000.</li>
<li>The US economy expanded at an annualized rate of 3% during the second quarter versus a revised 1.6% increase in the first quarter.</li>
<li>Pending home sales in the U.S. rose by 0.6% from the prior month in August versus market estimates of a 0.3% increase.</li>
<li>U.S. natural-gas stocks rose 47 billion cubic feet in the week ended Sept. 20, compared to market estimates of a 52 bcf gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41045737/top-3-materials-stocks-youll-regret-missing-this-quarter">Top 3 Materials Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

KTTA

MDXH

RYDE

TBIO

Dow Surges Over 250 Points; Accenture Earnings Top Views

<h3>Gainers</h3>
<ul>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) shares increased by 28.8% to $0.56 during Thursday's regular session. The market value of their outstanding shares is at $18.3 million. </li>
<li>BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) shares increased by 16.5% to $4.73. The company's market cap stands at $88.0 million. </li>
<li>Laser Photonics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>) stock increased by 14.23% to $13.59. The company's market cap stands at $166.4 million. </li>
<li>Nano Nuclear Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) stock moved upwards by 14.0% to $14.41. The company's market cap stands at $434.1 million. </li>
<li>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) shares moved upwards by 13.18% to $0.83. The company's market cap stands at $16.4 million. The company's, H1 earnings came out 2 days ago. </li>
<li>Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) stock moved upwards by 12.86% to $3.12. The company's market cap stands at $361.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ryde Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#AMEX">RYDE</a>) shares fell 32.3% to $0.78 during Thursday's regular session. The market value of their outstanding shares is at $16.3 million. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) shares declined by 21.55% to $0.07. The market value of their outstanding shares is at $3.6 million. </li>
<li>Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) shares decreased by 15.86% to $53.53. The company's market cap stands at $3.4 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>XCHG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCH#NASDAQ">XCH</a>) shares declined by 14.71% to $9.86. The company's market cap stands at $584.9 million. </li>
<li>Shimmick (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIM#NASDAQ">SHIM</a>) stock declined by 9.1% to $2.3. The market value of their outstanding shares is at $77.2 million. </li>
<li>Falcons Beyond Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBYD#NASDAQ">FBYD</a>) shares declined by 8.36% to $9.42. The market value of their outstanding shares is at $108.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AZUL

BlackSky Technology Inc. Class A Common Stock

BKSY

FBYD

LASE

SHIM

XPON

12 Industrials Stocks Moving In Thursday's Intraday Session

B of A Securities analyst Ruplu Bhattacharya maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Neutral and lowers the price target from $85 to $70.

B of A Securities Maintains Neutral on Concentrix, Lowers Price Target to $70

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 200 points on Thursday.
The Dow traded up 0.47% to 42,110.56 while the NASDAQ rose 0.19% to 18,117.40. The S&amp;P 500 also rose, gaining, 0.21% to 5,734.09.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/09/41045161/how-to-earn-500-a-month-from-costco-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Costco Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Materials shares jumped by 1.8% on Thursday.
In trading on Thursday, energy shares fell by 1.9%.
Top Headline
U.S. initial jobless claims fell by 4,000 from the prior week to 218,000 during the period ending September 21, compared to estimates of 225,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) shares shot up 71% to $3.96 after the company announced a partnership with Beckman Coulter Life Sciences to revolutionize DNA and mRNA synthesis.</li>
<li>Shares of Pasithea Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) got a boost, surging 66% to $6.37 after the company announced safety, tolerability, pharmacokinetic and preliminary efficacy data from the first 2 cohorts of patients in its Phase 1 clinical trial of PAS-004.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares were also up, gaining 25% to $5.00.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) shares dropped 16% to $53.65 following mixed third-quarter financial results.</li>
<li>Shares of Ryde Group Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYDE#NYSE">RYDE</a>) were down 30% to $0.81 after the company announced a $4.5 million public offering at $0.85 per unit.</li>
<li>MDxHealth SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) was down, falling 21% to $2.00 after the company announced the pricing of a $40 million offering of 20 million shares at $2.00 per share</li>
</ul>
Commodities In commodity news, oil traded down 2.4% to $68.00 while gold traded up 0.2% at $2,688.80.
Silver traded up 1.3% to $32.435 on Thursday, while copper rose 2.9% to $4.6195.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.13%, Germany's DAX climbed 1.52% and France's CAC 40 jumped 2.08%. Spain's IBEX 35 Index rose 1.39%, while London's FTSE 100 rose 0.12%.
Bank lending to households in the Eurozone increased by 0.6% year-over-year to €6.891 trillion in August compared to a 0.5% rise in the prior month. The GfK Consumer Climate Indicator for Germany climbed to a reading of -21.2 heading into October versus a revised reading of -21.9 in the prior period.
Asia Pacific Markets
Asian markets closed mostly higher on Thursday, with Japan's Nikkei 225 jumping 2.79%, Hong Kong's Hang Seng Index jumping 4.16%, China's Shanghai Composite Index gaining 3.61% and India's BSE Sensex gaining 0.78%.
Hong Kong&#8217;s trade deficit widened to $33.1 billion in August versus $25.6 billion in the year-ago month.
Economics
<ul>
<li>U.S. core PCE prices increased by 2.8% from the prior quarter during the second quarter compared to a 3.7% gain in the previous period.</li>
<li>U.S. durable goods orders came in mostly unchanged from the previous month in August versus the revised 9.8% jump in the earlier period.</li>
<li>U.S. initial jobless claims fell by 4,000 from the prior week to 218,000 during the period ending September 21, compared to estimates of 225,000.</li>
<li>The US economy expanded at an annualized rate of 3% during the second quarter versus a revised 1.6% increase in the first quarter.</li>
<li>Pending home sales in the U.S. rose by 0.6% from the prior month in August versus market estimates of a 0.3% increase.</li>
<li>U.S. natural-gas stocks rose 47 billion cubic feet in the week ended Sept. 20, compared to market estimates of a 52 bcf gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41045737/top-3-materials-stocks-youll-regret-missing-this-quarter">Top 3 Materials Stocks You&#8217;ll Regret Missing This Quarter</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Intraday Update

ADPT

Crude Oil Down Over 2%; US Initial Jobless Claims Fall

Barrington Research analyst Vincent Colicchio maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Outperform and lowers the price target from $84 to $70.

Barrington Research Maintains Outperform on Concentrix, Lowers Price Target to $70

Canaccord Genuity analyst Joseph Vafi maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Buy and lowers the price target from $125 to $100.

Canaccord Genuity Maintains Buy on Concentrix, Lowers Price Target to $100

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Thursday.
Shares of Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) fell sharply in today's pre-market trading following mixed <a href="https://www.benzinga.com/news/earnings/24/09/41035576/concentrix-stock-falls-after-mixed-q3-results-ix-hello-genai-launch-annoucement">third-quarter financial results.</a>
Concentrix reported quarterly earnings of $2.87 per share, which missed the analyst consensus estimate of $2.93 per share. Quarterly revenue came in at $2.387 billion, which beat the analyst consensus estimate of $2.382 billion.
Concentrix shares dipped 13.8% to $54.79 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>One Liberty Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLP#NYSE">OLP</a>) shares dipped 26.3% to $20.02 in pre-market trading.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) shares fell 15% to $10.59 in pre-market trading after the company announced its intention to offer $125 million of exchangeable senior notes due 2029 in a private offering.</li>
<li>Critical Metals Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) shares declined 8.3% to $6.00 in pre-market trading after dipping over 8% on Wednesday.</li>
<li>CarMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) shares declined 7.3% to $69.02 in pre-market trading following downbeat quarterly earnings.</li>
<li>Armada Hoffler Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) declined 7.3% to $11.00 in pre-market trading. Armada Hoffler announced upsizing and pricing of public offering of common stock.</li>
<li>Sonos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONO#NASDAQ">SONO</a>) shares fell 6% to $11.86 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41024505/top-5-industrials-stocks-that-may-collapse-in-q3">Top 5 Industrials Stocks That May Collapse In Q3</a></li>
</ul>

CRML

SONO

Concentrix Reports Weak Earnings, Joins CarMax And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

WIIM

Concentrix shares are trading lower following mixed Q3 financial results.

Shares of Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) rose sharply in today's pre-market trading session after the company announced a partnership with Beckman Coulter Life Sciences to revolutionize DNA and mRNA synthesis.
Telesis Bio reached a new partnership with laboratory automation and innovation company Beckman Coulter Life Sciences to create efficient and scalable biofoundries and deliver<a href="https://www.benzinga.com/general/biotech/24/09/41035436/telesis-bio-stock-is-soaring-wednesday-whats-going-on"> solutions for DNA synthesis</a>.
Telesis Bio shares jumped 109.9% to $4.87 in the pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Kintara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) rose 41.8% to $0.2375 in pre-market trading. Kintara Therapeutics recently announced adjournment of special meeting of stockholders until Oct. 4.</li>
<li>Fangdd Network Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUO#NASDAQ">DUO</a>) shares rose 22.3% to $0.6234 in pre-market trading after declining 7% on Friday.</li>
<li>NuCana plc  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 20.7% to $3.68 in pre-market trading after the company announced a U.S. patent grant covering its NUC-7738 composition-of-matter.</li>
<li>Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) gained 15.5% to $110.61 in pre-market as the company reported better-than-expected fourth-quarter financial results. The company reported fourth-quarter revenue of $7.75 billion, beating the consensus estimate of $7.635 billion. The company reported fourth-quarter adjusted earnings of $1.18 per share, beating analyst estimates of $1.13 per share, according to Benzinga Pro.</li>
<li>Gaotu Techedu Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOTU#NYSE">GOTU</a>) shares rose 14.8% to $3.34 in pre-market trading after falling around 5% on Wednesday.</li>
<li>Sonnet BioTherapeutics Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) rose 14.2% to $0.83 in pre-market trading. Sonnet BioTherapeutics shares dipped 20% on Wednesday after the company announced a 1-for-8 reverse stock split.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) shares gained 13.6% to $0.2737 in pre-market trading after rising around 5% on Wednesday.</li>
<li>Kanzhun Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) shares surged 13.5% to $16.20 in pre-market trading after falling 6% on Wednesday.</li>
<li>American Lithium Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLI#NASDAQ">AMLI</a>) gained 8.7% to $0.5297 in pre-market trading after gaining over 11% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>VS MEDIA Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSME#NASDAQ">VSME</a>) fell 23.6% to $1.16 in pre-market trading after jumping 22% on Wednesday.</li>
<li>MDxHealth SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXH#NASDAQ">MDXH</a>) shares dipped 20.9% to $2.01 in pre-market trading after the company reported the pricing of offering of ordinary shares.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) shares fell 15% to $10.59 in pre-market trading after the company announced its intention to offer $125 million of exchangeable senior notes due 2029 in a private offering.</li>
<li>AtlasClear Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NASDAQ">ATCH</a>) fell 14.5% to $0.2547 in pre-market trading. AtlasClear Holdings named Mark S. Smith as a Board Member.</li>
<li>Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) shares declined 13.8% to $54.79 in pre-market trading following mixed third-quarter financial results.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) shares fell 13.8% to $0.11 in pre-market trading. NLS Pharmaceutics, on Wednesday, announced expected implementation of 1-for-40 reverse share split.</li>
<li>Seelos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEEL#NASDAQ">SEEL</a>) fell 13.4% to $0.2928 in today's pre-market trading after gaining 13% on Wednesday. The company announced a 1-for-16 reverse stock split.</li>
<li>ConnectM Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTM#NASDAQ">CNTM</a>) shares declined 12.3% to $1.00 in pre-market trading after declining 10% on Wednesday.</li>
<li>Armada Hoffler Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHH#NYSE">AHH</a>) declined 7.3% to $11.00 in pre-market trading. Armada Hoffler announced upsizing and pricing of public offering of common stock.</li>
<li>Sonos, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONO#NASDAQ">SONO</a>) shares fell 6% to $11.86 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41024505/top-5-industrials-stocks-that-may-collapse-in-q3">Top 5 Industrials Stocks That May Collapse In Q3</a></li>
</ul>

AMLI

ATCH

CNTM

GSX Techedu Inc. American Depositary Shares

GOTU

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

Kintara Therapeutics, Inc. - Common Stock

KTRA

NCNA

NLSP

SEEL

SONN

VSME

Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket

Concentrix Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) reported its third-quarter financial results after Wednesday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/09/g41034257/concentrix-reports-third-quarter-2024-results">details from the report.&nbsp;</a>
The Details: Concentrix reported quarterly earnings of $2.87 per share, which missed the analyst consensus estimate of $2.93 by 2.05%. Quarterly revenue came in at $2.387 billion, which beat the analyst consensus estimate of $2.382 billion and represents a 46.2% increase over the same period last year.
The company reported operating income of $153.2 million, a reduction year-on-year primarily due to increased amortization of intangibles and planned integration expenses associated with the company&#8217;s combination with Webhelp, which closed in the fourth quarter of 2023.
Read Next: <a href="https://www.benzinga.com/news/24/09/41028294/whats-going-on-with-snowflake-stock">What&#8217;s Going On With Snowflake Stock?</a>
Concentrix also announced the launch of iX Hello, a generative AI-powered solution for organizations to boost productivity and engagement within an on-brand, secure environment. iX Hello marks the first product launch in a suite of AI and GenAI technologies which the company has already deployed internally and with pre-launch clients.
&#8220;Our third quarter marked another quarter of solid revenue growth and operating results,&#8221; said Chris Caldwell, president and CEO of Concentrix. 
&#8220;We are also delighted to leverage our technology investments to bring our iX Hello product to market with velocity. We believe iX Hello helps augment our existing technology partner strategies, underscores the positive transformation of our business and reflects our strong competitive position as the world&#8217;s most trusted provider of intelligent experience solutions.&#8221;
Outlook: Concentrix sees fourth-quarter revenue in a range of $2.42 billion to $2.47 billion and adjusted earnings of between $2.90 and $3.16 per share. The company sees fiscal year 2024 revenue in a range of $9.591 billion to $9.641 billion and adjusted earnings of between $11.05 and $11.31 per share. 
CNXC Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Concentrix shares are down 14.02% after-hours at $54.70 at the time of publication Wednesday.&nbsp;
Read Also: <a href="https://www.benzinga.com/news/24/09/41011763/whats-going-on-with-intel-stock"> </a> • <a href="https://www.benzinga.com/news/24/09/41011763/whats-going-on-with-intel-stock">What&#8217;s Going On With Intel Stock?</a>
Photo: Shutterstock

Concentrix Stock Falls After Mixed Q3 Results, iX Hello GenAI Launch Annoucement

Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>), a global technology and services leader, today announced the release of iX Hello, a GenAI-powered self-service application designed to supercharge productivity and engagement quality, with high security.&nbsp;&nbsp;
iX Hello offers an out-of-the box solution for businesses to create virtual assistants for countless use cases — from data analysis to rapid language translations to internal self-service chatbots and more. The product acts as an assistant that securely integrates with leading Large Language Models (LLMs) as well as internal data sources, to cost-effectively boost productivity and quality of work within an on-brand, compliant, and secure environment.

Concentrix  Announced The Release Of iX Hello, A GenAI-Powered Self-Service Application Designed To Supercharge Productivity And Engagement Quality, With High Security

Guidance

Concentrix Sees Q4 Revenue at $2.42B-$2.47B, Adj. EPS $2.90-$3.16; Sees FY24 Revenue $9.591B-$9.641B, Adj. EPS $11.05-$11.31

Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) reported quarterly earnings of $2.87 per share which missed the analyst consensus estimate of $2.93 by 2.05 percent. The company reported quarterly sales of $2.387 billion which beat the analyst consensus estimate of $2.382 billion by 0.21 percent. This is a 46.20 percent increase over sales of $1.633 billion the same period last year.

Earnings Beats

Earnings Misses

Concentrix Q3 2024 Adj. EPS $2.87 Misses $2.93 Estimate, Sales $2.387B Beat $2.382B Estimate

Throughout the last three months, 4 analysts have evaluated Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Concentrix and provided 12-month price targets. The average target is $94.5, accompanied by a high estimate of $125.00 and a low estimate of $84.00. This upward trend is evident, with the current average reflecting a 5.59% increase from the previous average price target of $89.50.
<img src="https://www.benzinga.com/files/images/story/2024/1727103622_0_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Concentrix. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Vincent Colicchio</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ruplu Bhattacharya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Vafi</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$125.00</td>
<td>$125.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Concentrix. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Concentrix compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Concentrix's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Concentrix's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CNXC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Concentrix analyst ratings.</a>
<h2>Delving into Concentrix's Background</h2>
Concentrix Corp is a technology-enabled company specialized in customer engagement and customer management. The company provides end-to-end capabilities, including CX process optimization, technology innovation and design engineering, front- and back-office automation, analytics and business transformation services to clients in five primary industry verticals. The Company's verticals are technology and consumer electronics, retail, travel and e-commerce, communications and media, banking, financial services and insurance, and healthcare. Geographically, the company operates in Philippines, Unites States, India, Canada, Germany, Great Britain and others.
<h3>Concentrix: A Financial Overview</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Concentrix displayed positive results in 3 months. As of 31 May, 2024, the company achieved a solid revenue growth rate of approximately 47.44%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.
Net Margin: Concentrix's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.7%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.57%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Concentrix's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.53%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Concentrix's debt-to-equity ratio is below the industry average. With a ratio of 1.21, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 4 Analyst Recommendations For Concentrix

Barrington Research analyst Vincent Colicchio maintains Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) with a Outperform and maintains $84 price target.

Barrington Research Maintains Outperform on Concentrix, Maintains $84 Price Target

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Wednesday.
Shares of Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) rose during Wednesday's session following better-than-expected <a href="https://www.benzinga.com/news/earnings/24/08/40599429/kohls-q2-earnings-profit-beat-inventory-decline-margin-growth-and-more">second-quarter financial results.</a>
The company reported a net sales decline of 4.2% Y/Y to $3.525 billion, with comparable sales for the quarter decreasing 5.1% Y/Y. Total revenue stood at $3.732 billion. The analyst consensus estimate was $3.583 billion. EPS was 59 cents, beating the analyst consensus estimate of 44 cents.
Kohl&#8217;s shares climbed 5.6% to $20.71 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Waldencast plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WALD#NASDAQ">WALD</a>) jumped 41.5% to $4.0920 after the company reported second-quarter revenue growth.</li>
<li>AeroVironment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) gained 17.6% to $209.40 after multiple analysts upgraded the stock and raised their price targets.</li>
<li>VNET Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) gained 17.1% to $2.34 following second-quarter results.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) rose 12.3% to $5.45.</li>
<li>Bioceres Crop Solutions Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOX#NASDAQ">BIOX</a>) climbed 12.1% to $11.32. Bioceres Crop Solutions received green light for cultivation of Drought Tolerant HB4 Wheat in the United States.</li>
<li>Ambarella, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMBA#NASDAQ">AMBA</a>) surged 11.3% to $58.82 after the company reported better-than-expected second-quarter adjusted EPS and sales.</li>
<li>Box, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) gained 10.1% to $31.73 after the company reported better-than-expected second-quarter financial results and issued FY25 guidance above estimates.</li>
<li>MannKind Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) jumped 10.2% to $5.93. Oppenheimer analyst Steven Lichtman maintained MannKind with an Outperform and raised the price target from $10 to $12.</li>
<li>Westrock Coffee Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) gained 9.9% to $9.35. Westrock Coffee Company commenced warrant exchange offer and consent solicitation.</li>
<li>The Hain Celestial Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAIN#NASDAQ">HAIN</a>) gained 10.2% to $8.93. Hain Celestial Group, on Tuesday, reported better-than-expected quarterly adjusted EPS results</li>
<li>AvePoint, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVPT#NASDAQ">AVPT</a>) jumped 8.5% to $11.69 after the company announced it commenced an offer to purchase all outstanding public warrants to purchase shares of its common stock at $2.50 per share without interest.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) gained 8.2% to $28.04 following quarterly results.</li>
<li>Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) gained 4.4% to $75.49. B of A Securities analyst Ruplu Bhattacharya upgraded Concentrix from Underperform to Neutral and raised the price target from $65 to $85.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) rose 3.3% to $49.68.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40600771/ambarella-to-rally-around-61-here-are-10-top-analyst-forecasts-for-wednesday">Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday</a></li>
</ul>

AIXI

AMBA

AVAV

AVPT

BIOX

CHWY

HAIN

MNKD

VNET

WALD

WEST

Kohl's Posts Upbeat Q2 Earnings, Joins Box, Waldencast, AeroVironment And Other Big Stocks Moving Higher On Wednesday

Concentrix Corporation (CNXC) Q3 2024 Earnings Call Transcript

In a report released today, Divya Goyal from Scotiabank maintained a Buy rating on Concentrix (CNXC – Research Report), with a price target of $85....

Scotiabank Sticks to Their Buy Rating for Concentrix (CNXC)

Vincent Colicchio, an analyst from Barrington, maintained the Buy rating on Concentrix (CNXC – Research Report). The associated price target was lo...

Concentrix Corporation: Strong Buy on Robust Revenue Growth and Market Positioning

Baird initiates coverage on Concentrix with Outperform rating

As industries pivot towards a digital-first approach, AI's importance in streamlining business processes, driving innovation, and curbing costs has...

Concentrix (CNXC) Offers a New Bag of Tricks in GenAI Tech

Wolfe's tax loss selling stocks within industrials, tech, materials

This week, several dividend stocks are trading close to their 52-week lows. Here is a list of ten such stocks that are also reaching their ex-divid...

Ex-Dividend Date Nearing for These 10 Stocks – Week of October 21, 2024

An update from Concentrix ( ($CNXC) ) is now available. At a Special Meeting on October 28, 2024, the Company received stockholder approval to amen...

Concentrix Holds Special Meeting to Amend Charter

Concentrix: Significant Business Growth Driven By AI, And Cheap Valuation

Analyst David Koning of Robert W. Baird maintained a Buy rating on Concentrix (CNXC – Research Report), retaining the price target of $70.00. David...

Concentrix: A Resilient Investment Amid Automation Challenges and Attractive Valuation

AGCO

ALGM

ATKR

BILL

BRZE

BSBR

CFLT

CLVT

EPAM

FIVN

FRSH

GAIN

GTLB

GTLS

INTC

IPGP

LAND

LSCC

PATH

PAYC

POWI

PYCR

QLYS

SEDG

SIRI

SNAP

SNOW

TEAM

USAC

WOLF

Press Releases

Concentrix Named a Leader and Star Performer in Everest Group's Trust and Safety Services PEAK Matrix® Assessment 2024

Concentrix to Present at Upcoming Investor Conferences

General

Concentrix Debuts on the Fortune 500® List

Concentrix Schedules Release of Second Quarter 2024 Financial Results and Webcast of Investor Conference Call

Concentrix Reports Second Quarter 2024 Results

Concentrix Sets Bold Goals to Support People and Planet in New Sustainability Report

Concentrix Schedules Release of Third Quarter 2024 Financial Results and Webcast of Investor Conference Call

Concentrix Reports Third Quarter 2024 Results

Concentrix Introduces Intelligent Experience Technology Product Suite with Launch of iX Hello™

Concentrix to share new insights on AI and intelligent experiences at Web Summit 2024

Comments

Concentrix

Notizie

Ultime notizie per Concentrix (NASDAQ:CNXC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO